Target type: molecularfunction
Combining with vasopressin to initiate a change in cell activity. [GOC:ai]
Vasopressin receptor activity is a molecular function associated with transmembrane receptors that bind vasopressin, a hormone produced by the hypothalamus and released from the posterior pituitary gland. Vasopressin receptors play a crucial role in regulating a variety of physiological processes, including blood pressure, water reabsorption in the kidneys, and social behavior.
The binding of vasopressin to its receptor initiates a cascade of intracellular signaling events that lead to various cellular responses. The primary signaling pathway involves the activation of G protein-coupled receptors (GPCRs), specifically Gq/11 proteins. This activation leads to the production of inositol triphosphate (IP3) and diacylglycerol (DAG), which in turn activate protein kinase C (PKC) and calcium signaling.
Vasopressin receptor activity is involved in several key functions:
* **Regulation of blood pressure:** Vasopressin receptors, particularly the V1 receptor subtype, are located on vascular smooth muscle cells. The binding of vasopressin to these receptors triggers vasoconstriction, leading to an increase in blood pressure.
* **Water reabsorption in the kidneys:** Vasopressin receptors, specifically the V2 receptor subtype, are located on the collecting ducts of the kidneys. The binding of vasopressin to these receptors stimulates the insertion of aquaporin-2 water channels into the cell membrane, increasing water reabsorption and urine concentration.
* **Social behavior:** Vasopressin receptors play a role in social recognition, pair bonding, and aggression. The specific role of vasopressin receptors in social behavior varies between species.
* **Other functions:** Vasopressin receptor activity is also implicated in regulating stress responses, regulating blood clotting, and modulating the immune system.
Overall, vasopressin receptor activity plays a critical role in maintaining homeostasis and regulating essential physiological processes. The diverse downstream signaling pathways activated by these receptors contribute to their wide range of biological functions.'
"
Protein | Definition | Taxonomy |
---|---|---|
Oxytocin receptor | An oxytocin receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P30559] | Homo sapiens (human) |
Neuropeptide S receptor | A neuropeptide S receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q6W5P4] | Homo sapiens (human) |
Vasopressin V1b receptor | A vasopressin V1b receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P47901] | Homo sapiens (human) |
Vasopressin V1a receptor | A vasopressin V1a receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P37288] | Homo sapiens (human) |
Vasopressin V2 receptor | A vasopressin V2 receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P30518] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
clotrimazole | conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes | antiinfective agent; environmental contaminant; xenobiotic | |
itraconazole | piperazines | ||
propranolol | propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3. Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. | naphthalenes; propanolamine; secondary amine | anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic |
relcovaptan | relcovaptan: a nonpeptide vasopressin V1 receptor antagonist; structure given in first source | proline derivative | |
opc 21268 | OPC 21268: structure given in first source; vasopressin V1 receptor antagonist | ||
mozavaptan | mozavaptan: aquaretic agent; vasopressin V2 receptor antagonist; structure given in first source | benzamides | aquaretic |
conivaptan | conivaptan : The amide resulting from the formal condensation of 4-[(biphenyl-2-ylcarbonyl)amino]benzoic acid with the benzazepine nitrogen of 2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine. It is an antagonist for two of the three types of arginine vasopressin (AVP) receptors, V1a and V2. It is used as its hydrochloride salt for the treatment of hyponatraemia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). | benzazepine | aquaretic; vasopressin receptor antagonist |
satavaptan | satavaptan: a vasopressin V2 receptor antagonist; structure given in first source | ||
lixivaptan | |||
tolvaptan | benzazepine; benzenedicarboxamide | aquaretic; vasopressin receptor antagonist | |
ritonavir | ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver. Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A. | 1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas | antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic |
oxytocin | oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour. Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION. | heterodetic cyclic peptide; peptide hormone | oxytocic; vasodilator agent |
saquinavir | saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease. Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A. | L-asparagine derivative; quinolines | antiviral drug; HIV protease inhibitor |
diethylstilbestrol | diethylstilbestrol : An olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups. Diethylstilbestrol: A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) | olefinic compound; polyphenol | antifungal agent; antineoplastic agent; autophagy inducer; calcium channel blocker; carcinogenic agent; EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; endocrine disruptor; xenoestrogen |
deaminooxytocin | demoxytocin : A heterodetic cyclic peptide that is the synthetic analog of the peptide hormone oxytocin where the free amino group in the half-cystine residue is replaced by hydrogen. The mechanism of action and pharmacological properties of demoxytocin and oxytocin are similar. The drug affects the permeability of the cell membrane, increasing the content of calcium ions in smooth muscle cells, thereby increasing its contraction. It stimulates the contraction of smooth muscles of the uterus, as well as stimulating the contraction of myoepithelial cells of the mammary gland, and enhances the secretion of milk. | heterodetic cyclic peptide | oxytocic |
arginine vasopressin | Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. | vasopressin | cardiovascular drug; hematologic agent; mitogen |
opc 51803 | OPC 51803: a nonpeptide vasopressin V(2)-agonist; structure in first source | ||
quercetin | 7-hydroxyflavonol; pentahydroxyflavone | antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger | |
atosiban | oligopeptide | ||
deamino arginine vasopressin | Deamino Arginine Vasopressin: A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR. | heterodetic cyclic peptide | diagnostic agent; renal agent; vasopressin receptor agonist |
l 372662 | L 372662: structure in first source | ||
way-151932 | WAY-151932: structure in first source | ||
l 371257 | L 371257: structure given in first source | ||
pmx 53 | |||
vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(o- methyl-l-tyrosine)-8-l-arginine- | vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine-: highly potent antagonist of vasopressor response to arginine-vasopressin; structure in first source | ||
l 368899 | |||
ssr 149415 | |||
gsk221149a | GSK221149A: highly selective oxytocin receptor antagonist; structure in first source | dipeptide | |
sha 68 | |||
epelsiban | epelsiban: structure in first source | dipeptide | |
carbetocin | carbetocin : Oxytocin in which the hydrogen on the phenolic hydroxy group is substituted by methyl, the amino group on the cysteine residue is substituted by hydrogen, and the sulfur of the cysteine residue is replaced by a methylene group. A synthetic carba-analogue of oxytocin, it is used to control bleeding after giving birth. Like oxytocin, it causes contraction of the uterus. | heterodetic cyclic peptide | oxytocic |
vasopressin, 1-deamino-4-val-8-arg- | |||
nitd 609 | NITD 609: an antimalarial and coccidiostat; structure in first source | ||
obe001 | OBE001: an oxytocin receptor antagonist | ||
(6-chloro-1-(2-(dimethylamino)ethyl)indol-3-yl)-spiro(1h-isobenzofuran-3,4'-piperidine)-1'-yl-methanone | (6-chloro-1-(2-(dimethylamino)ethyl)indol-3-yl)-spiro(1H-isobenzofuran-3,4'-piperidine)-1'-yl-methanone: a vasopressin 1a receptor antagonist; structure in first source | ||
way 267464 |